The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Related articles:
Related suggestion:
Adzija, Kosta guide Boston to 2De La Cruz homers in the 9th inning as the Marlins beat the Cubs 3Ryan Garcia knocks Devin Haney down 3 times and hands his amateur rival his first pro lossZack Wheeler has noSuper Rugby: playoffs picture clears but system raises questionsHong, Young lead Stanford men's gymnastics to 5th consecutive national titleMoment cops shoot dead 67Taylor Swift sends secret message to Travis Kelce in So High School's lyric videoConditions improve for students shot in Maryland park on 'senior skip day'Heartbreaking final photo of nine
2.8394s , 6605.828125 kb
Copyright © 2024 Powered by It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start? ,International Intuition news portal